Forskolin

For research use only. Not for use in humans.

目录号：S2449 别名： Coleonol

Forskolin Chemical Structure

Molecular Weight(MW): 410.5

Forskolin在各种各样细胞类型中，是一种普遍存在的真核细胞腺苷酸环化酶（AC）激活剂，在细胞生理学研究中，通常用来提高cAMP水平。Forskolin 还可激发 PXR 和 FXR的活性而诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1144.16 现货
RMB 903.37 现货
RMB 2229.31 现货
RMB 3029.97 现货
RMB 4679.71 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Forskolin发表文献51篇：

产品安全说明书

cAMP抑制剂选择性比较

生物活性

产品描述 Forskolin在各种各样细胞类型中，是一种普遍存在的真核细胞腺苷酸环化酶（AC）激活剂，在细胞生理学研究中，通常用来提高cAMP水平。Forskolin 还可激发 PXR 和 FXR的活性而诱导自噬。
靶点
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外研究

Forskolin可以使膜，细胞或组织制备液中cAMP含量上升。Forskolin 不仅可以活化AC 而且可以与某些其它蛋白相互作用，包括葡萄糖转运蛋白和离子通道。Forskolin能够促进9种不同独立AC形式的活化，虽然对AC9效率有点低，这可以用于提供一种鉴定和量化G蛋白 (Gs)–AC复合物高亲和性结合位点的方法。G蛋白偶联受体活化G蛋白有助于细胞中Forskolin刺激的cAMP 产生，因为 G蛋白-Forskolin对AC活性有增强作用[1]。Forskolin在不与细胞表面受体相互作用前提下刺激腺苷酸环化酶活性。在脂肪细胞中Forskolin's促进 cAMP产生进而可以抑制嗜碱性粒细胞和肥大细胞脱颗粒作用以及组胺释放，降低血压、眼内压，抑制血小板聚集，促进血管舒张，支气管扩张和甲状腺激素分泌，刺激脂肪分解。Forskolin 抑制血小板活化因子 (PAF)的结合, 这种抑制不依赖于cAMP形成可能是 Forskolin's 直接作用于 PAF或者通过干扰PAF与它的受体结合实现的。Forskolin似乎对多种膜转运蛋白也有效果并且可以抑制脂肪细胞，红细胞，血小板，和其他细胞中的葡萄糖运输。Forskolin也被用于治疗青光眼[2]。
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 M1ny[2Z2dmO2aX;uJGF{e2G7 NIT4UXQyOCEQvF2= M2jNT|YhcA>? M1\OR4lv[3KnYYPld{BxcG:|cHjvdplt[XSrb36gc4Yhd3[ncnX4dJJme3OnZDDLUGhNOyCjdDDTOFM{ NWTpOm1tOjZ2M{W0PVg>
Mo-DCs MWjGeY5kfGmxbjDBd5NigQ>? M{\CZVUxKM7:TR?= MW[yOQKBkWh? NG\l[3Fxem:vb4Tld{BKVC1{MzDwdo9lfWO2aX;uJIlvKHSqZTDzeZBmem6jdHHueEBw\iC8eX3vd4FvKHO2aX31cIF1\WRiTX:tSGN{yqB? NFXKWpUzPjRzMkm0PC=>
RBMECs  MWfGeY5kfGmxbjDBd5NigQ>? MnXxOeKh|ryP M2\IclHDqGh? NIHXXmpjdG:la4OgeIhmKFKjY{GgbY5i[3SrdnH0bY9vKGmwZIXj[YQh[nliRV3BVE1KUQ>? M3XDNVI3OzV6MEO5
INA-6 M4Lp[mNmdGxiVnnhZoltcXS7IFHzd4F6 NVHScHRbOC1zMECg{txO NIT5OJU4OuLCiXi= NUjjOXFkcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> NV7tNHc6OjZ|ME[2NlQ>
OPM-2 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIPX[oExNTFyMDFOwG0> M4XQblcz6oDLaB?= MULpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= NX3oSnVLOjZ|ME[2NlQ>
U266 MonYR4VtdCCYaXHibYxqfHliQYPzZZk> Mk[xNE0yODBizszN MnPwO|LjiImq NGH1VGlqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NUXj[XdFOjZ|ME[2NlQ>
H929 M3T2ZWNmdGxiVnnhZoltcXS7IFHzd4F6 Mn7rNE0yODBizszN M1TBRlcz6oDLaB?= MULpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= Mn;oNlY{ODZ4MkS=
RPMI 8226 NULZXXFCS2WubDDWbYFjcWyrdImgRZN{[Xl? Ml;5NE0yODBizszN NVXJWlNNPzMkgJno MX\pcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MYWyOlMxPjZ{NB?=
MDCK  M1y4UWZ2dmO2aX;uJGF{e2G7 NULUbJdnOTBiwsXN MVuyOEBp MoPuSG1UVw>? MlzJeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhXEeILd8yNUBidmRiQ2THSuKh NYO5W4ZKOjZ{MEKzOVI>
MDCK  M4[2Z2Z2dmO2aX;uJGF{e2G7 NVzsRXFvOTBiwsXN M2nhZlI1KGh? NYDtb4g4TE2VTx?= MojwbY5pcWKrdIOgeIhmKGmwY4LlZZNm\CCneIDy[ZN{cW:wIH;mJGZPKGOjdYPl[EBjgSCWR1[t{tIy Mni0NlYzODJ|NUK=
Spinal cords  M17Le2Z2dmO2aX;uJGF{e2G7 Mmn6NeKh|ryP MXKzNEBucW5? MYPzeIlufWyjdHXzJINCVVBibHX2[Yx{ MXeyOlEzPjl{Nh?=
BeWo  MoDNSpVv[3Srb36gRZN{[Xl? M{Hkb|I26oDLzszN MYiyOE81QC95MjDo MVjs[YFleyC2bzDhckBqdmO{ZXHz[UBqdiC2aHWg[ZhxemW|c3nvckBw\iCxdHjldkBnfXOrb36gcYFzc2W{cx?= NXv4dZQ6OjZyNUO1OFk>
bovine oocytes NFvJfG9HfW6ldHnvckBCe3OjeR?= MojBNVAxyqEQvF2= NH63NosyOsLiaB?= NFnVTFZqdmirYnn0d{B1cGViZX\m[YN1KG:oIF7QVGEh[W6mL3;yJG5RWENidH:gd5RqdXWuYYTlJJJme3WvcITpc44hd2ZibXXpc5Nqew>? NW\oXFNsOjZyNUG2NVE>
Caco-2  NH;P[4hHfW6ldHnvckBCe3OjeR?= MVWwMlEwOS9zMDFOwG0> MYCyNOKhdWmw MYjpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClQV3QJIxmfmWucx?= MkGwNlYxPDlzMEK=
Caco-2  Mmi5SpVv[3Srb36gRZN{[Xl? NYXDbIkyOC5zL{GvNVAh|ryP Mn7mNlQhcA>? NXjL[20zcW6lcnXhd4V{KE2UUEKgdJJwfGWrbjDs[ZZmdA>? MVeyOlA1QTFyMh?=
AML-12  MUnGeY5kfGmxbjDBd5NigQ>? NEXYe3gzOCEQvF2= MYqzJIg> M1[wSJVxemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ibHX2[Yx{KGG2IGTodk01OTFiYX7kJHNmei12OUO= NYqwXphWOjZyNEi5PFU>
AML-12  MmHmSpVv[3Srb36gRZN{[Xl? M3;0Z|IxKM7:TR?= NXTER2t6OS16IHi= M1\6OIlv[3KnYYPld{BodHWlb4PlJJBzd2S3Y4Tpc44> NEfLcnMzPjB2OEm4OS=>
AML-12  NYDTTYtVTnWwY4Tpc44hSXO|YYm= MX6yNEDPxE1? NV7QbZluOyCq NHe0c|l2eC2{ZXf1cIF1\XQEoGDnZ|FiNMLiUHXwZ4stKGGwZNMgS|Zx[8LibWLORUBt\X[nbIO= MYOyOlA1QDl6NR?=
AML-12  NYr0RXJxTnWwY4Tpc44hSXO|YYm= M372WFIxKM7:TR?= NWXVTpp{OyCq NXL0c|I1cW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25ib3[gR3JVSzMEoB?= MXiyOlA1QDl6NR?=
RBMECs NUHYfYtDTnWwY4Tpc44hSXO|YYm= MmDrOeKh|ryP MlvoNUBp M4j4colvcGmkaYTzJGVOSVBvSVmtbY5lfWOnZDDpcoFkfGm4YYTpc44hd2ZiUnHwNeKh MUCyOlA1PDZ4Mx?=
EndoC-βH1 NHjxVGdHfW6ldHnvckBCe3OjeR?= MlLvOeKh|ryP NX60VodQOSCq NGrxWXNxd3SnboTpZZRmeyCpbIXjc5NmNWmwZIXj[YQhcW6|dXzpckB{\WO{ZYTpc44hcW5idHjlJJBz\XOnbnPlJI9nKGeudXPvd4U> MmS2NlYxOjh3NkK=
EndoC-βH1 NUXTWWlXTnWwY4Tpc44hSXO|YYm= MlTROeKh|ryP M32yVVEhcA>? NXrX[4NqdGWjZIOgeI8h[SC|dILvcoch[0GPUDDpcoNz\WG|ZR?= NHezcWMzPjB{OEW2Ni=>
SH-SY5Y NUPhdWwzTnWwY4Tpc44hSXO|YYm= MYSzNEDPxE1? M{fmO|MxKG2rbh?= NH[3b|ZFVVOR M3jtNZNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBi[3SrdnH0bY9vKG:oIGDLRS=> M3jlT|I3ODJ3MUO3
PC-3 MXTGeY5kfGmxbjDBd5NigQ>? Mk\QOFAhyrWP NX\uZo5sOiCq NEfmN2pFVVOR Ml7GcIVi\HNidH:gVHAzSSCjY4TpeoF1cW:w NWr4TYFIOjZyMkO4N|Y>
PC-3 M{XubmNmdGxiVnnhZoltcXS7IFHzd4F6 M3nBV|QxKML3TR?= NIHZcmgzPC92OD:3NkBp MVrEUXNQ MYnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlidHnt[UBl\XCnbnTlcpRtgQ>? NGLHPYMzPjB{M{izOi=>
SCG M1v3bWZ2dmO2aX;uJGF{e2G7 NFrhe4MzOCEQvF5CpC=> NF7pfo9FVVOR NFXaTZBz\X[ncoPpZox6KHO3cIDy[ZN{\XNiSVvWJJdqfGhiYTDJR|UxKG:oIEK0MlQh|ryP M4W0bFI2QTZ{MUOy
HEK-293 NWD3XoR2TnWwY4Tpc44hSXO|YYm= NUn2UphuOzVizszNxsA> NF\4RmpFVVOR MXnpcoR2[2W|IHGgZ49ve3CrY4XveZMh6oDeaX7hZ5RqfmG2aX;u5qCeKG:oIITo[UBMfjJwMTDjeZJz\W62 MYqyOVk3OjF|Mh?=
SCG MV;GeY5kfGmxbjDBd5NigQ>? M4naflExOCEQvF5CpC=> NEPCdnhFVVOR MVry[YR2[2W|IITo[UBmgGOrdHHibYxqfHlib3[gV2NIKG6ndYLvcpM> M1zKe|I2QTZ{MUOy
PCCL3 NX;STVhXTnWwY4Tpc44hSXO|YYm= NYDJb4FVOTBiwsXN NXm2TYoyOjRiaB?= NUTaRm1U\W6qYX7j[ZMhTHWReEKgdJJwdW:2ZYKgeJJidnOlcnnweIlwdiCjY4Tpeol1gcLi4pEL NV;iVVJlOjV7NkC5OVY>
3T3-L1 preadipocytes NUnKbYQ1TnWwY4Tpc44hSXO|YYm= NV7xRpp3OTBizszNxsA> MUexNkBp MY\pcoR2[2W|IFPSSWIheGixc4Doc5J6dGG2aX;uJIFv\CCFL1XCVO6zKGW6cILld5Nqd25? NF23dGIzPTl{OEC1PC=>
H295R  MmXKSpVv[3Srb36gRZN{[Xl? MoLyNVDDqM7:TR?= NE\kcmk1QMLiaB?= MomxbY5kemWjc3XzJJN1\XKxaXSgcYV1[WKxbHn0[ZMhcW5idHjlJIFv\HKxZ3XuMEBucW6ncnHsc{0h[W6mIHfseYNw[2:{dHnjc4llKHCjdHj3ZZl{ MkHSNlU5Pjl3NU[=
PBMC NWD0TZBtTnWwY4Tpc44hSXO|YYm= MXu1NOKh|ryP NWr3XGxIOjUEoHlCpC=> MWDpcohq[mm2czD0bIUhcW6lcnXhd4VlKHOnY4LleIlwdiCxZjDUUmYhcW6mdXPl[EBjgSC2aHWgSHBG MUWyOVg3PjB5OR?=
GLUTag  M3TqOGZ2dmO2aX;uJGF{e2G7 NHXFdIoyOOLCidM1US=> NWrUPI1YOC9{L{SgbC=> NGLNVoN{fGmvdXzheIV{KEeOUD2xJJNm[3KndHnvckBkd3S{ZXH0[YQhf2m2aDDJRm1Z NGXsR2gzPTh|Mk[zNS=>
GLUTag  NYfWWGhYTnWwY4Tpc44hSXO|YYm= MnrINVDjiIoEtV2= MkLKOEBp MnvabY5kemWjc3XzJJRp\SCyQ2LFRkBt\X[nbIOge4l1cCC2aHWgTWJOYA>? NInFVZYzPTh|Mk[zNS=>
BAECs M{DCVmZ2dmO2aX;uJGF{e2G7 MlP2NlUh|ryP NX7sZot1OjRiaB?= MknI[Y5p[W6lZYOgeIhmKGGldHn2ZZRqd25ib3[gVHBCWs7zIHL5JFUh|ryPIILld5ZmemG2cn;sMEBVPEiVLDDvdkA1NVCDUB?= Ml;MNlU4QTh6Mk[=
PC12 MWHGeY5kfGmxbjDBd5NigQ>? NYK4NXJVOjYEoN88US=> NWDmRYt7PDhiaB?= MlvLZYN1cX[jdHXzJINCVVB? MWGyOVc3QTNyNR?=
GH3 M33MTGZ2dmO2aX;uJGF{e2G7 NISyXYYyyqEQvF2= NVLySGZMPi2q NHewbnhifHSnboXheIV{KHSqZTDjc5Jz\WyjdHnvckBj\XS5ZXXuJHBTVCCjbnSgRo1idDFiZYjwdoV{e2mxbh?= NVPhR3BuOjV5MkewNVg>
GH3 Mn\USpVv[3Srb36gRZN{[Xl? MWSxxsDPxE1? MYe2MYg> NFvTPJZqdmS3Y3XzJHBTVCCjbnSgRo1idDFuIHL1eEBvd3RiQ3zvZ4stKG2UTlGg[ZhxemW|c3nvci=> MoLmNlU4OjdyMUi=
BeWo NHPx[W9HfW6ldHnvckBCe3OjeR?= MUmxNQKBks7:TdMg MX63NkBp MYfEUXNQ M2HxWY1m\GmjdHXzJGJmX29iY3XscEBlcW[oZYLlcpRq[XSrb36= M1zOXFI2PzF|NEK1
oocytes NFGzbYxHfW6ldHnvckBCe3OjeR?= NIO0Opk2KM7:TR?= NUXpVYpzOjRiaB?= M2r3U4F1fGWwdXH0[ZMhemhvaX7zeYxqdiCjY4Tpc44hd25ib3;jfZRmKEeYQlSgd4lodmmoaXPhcpRtgcLi NX\HVlZuOjV5MEe4OVQ>
SC NXvBRWV{TnWwY4Tpc44hSXO|YYm= M4HPe|AvPSEQvF2= MoWzNlQhcA>? M2\MWI1qdWmla4OgeIhmKGWoZnXjeEBw\iClQV3QJIFv[WyxZ4Ogc44hVzFiYX7kJG1DWCCneIDy[ZN{cW:w NVzGd3BrOjV5MEW4O|Q>
SC M{G3bWZ2dmO2aX;uJGF{e2G7 M4DtcVAvPSEQvF2= Ml\VO|IhcA>? MXLpcoNz\WG|ZYOgZo91cCCNcn;4MVIxKGGwZDDPNUBmgHC{ZYPzbY9vKGmwIHH4c44uemWuYYTl[EBUS3NiYoX0JI9vdHliS4LvfE0zOMLi MmLRNlU4ODV6N{S=
UACC-647  MkTZSpVv[3Srb36gRZN{[Xl? MYDEUXNQ MXns[YFleyC2bzDhJJJqe2ViaX6gZ2FOWCCuZY\lcJMhMEWFNUFCpF3DqDJyLkO5xsDPxE1r M1:yS|I2PzB|MEK1
UACC-647  MmrjSpVv[3Srb36gRZN{[Xl? MWexNOKh|ryP MnL1NVUhdWmw MWjEUXNQ MX3pcohq[mm2czDFVmsheGixc4Doc5J6dGG2aX;u MVSyOVcxOzB{NR?=
UACC-647  M3LHemZ2dmO2aX;uJGF{e2G7 M33m[|ExyqEQvF2= MonyNVUhdWmw NXGzdWl[TE2VTx?= NULtXFczcW6lcnXhd4V{KGWHRkKgdIhwe3Cqb4L5cIF1cW:wIHzleoVte8Li M{fQSlI2PzB|MEK1
SH-SY5Y  MWHGeY5kfGmxbjDBd5NigQ>? MXGxNOKh|ryP MXmxxsBpyqB? NGfMcoJqdmO{ZXHz[ZMhVFWFIHHjeIl3cXS7 M{fPTFI2PTl5NEOz
SH-SY5Y  M2KxWmZ2dmO2aX;uJGF{e2G7 NIPocpYyOMLizszN NX[yfmdVOcLiaNMg MmXObY5kemWjc3XzJGFISzFibWLORUBt\X[nbB?= NIjGW3kzPTV7N{SzNy=>
hADSCs MnrtSpVv[3Srb36gRZN{[Xl? MVK15qCKyrWP M1O0TVMxKG2rbh?= M3H1[4lv[3KnYYPld{BkSU2SIHzleoVtew>? MonFNlU2QTF7MEi=
HEK293  MljrSpVv[3Srb36gRZN{[Xl? NFXlNoM26oDLwsXN NYTMfFQ2OzBibXnu MmXybY5kemWjc3XzJINCVVBibHX2[Yx{ NVL3fpR2OjV3OUG5NFg>
3T3-L1 M4m2RmZ2dmO2aX;uJGF{e2G7 MnjlNk42NzVizszN M1PxO|I1KGkEoB?= MoDYd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQWTHUEBxem:2ZXnuJIV5eHKnc4Ppc44h[XRiYXzsJIRwe2W|IITld5Rm\A>? NFP2fFEzPTV7MEW5Oy=>
OCI-Ly1  NX\ufmV4TnWwY4Tpc44hSXO|YYm= NXf4UJBuPDEEoN88US=> MW[xxsBpyqB? MnXlSG1UVw>? M33yUolv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z NH7SbIEzPTV5NkKyNC=>
OCI-Ly18  M2HtRWZ2dmO2aX;uJGF{e2G7 NVzmR2pFPDEEoN88US=> NGTP[JYyyqCqwrC= M3T3Z2ROW09? M3fSN4lv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z MWSyOVU4PjJ{MB?=
BeWo NWDzTIduTnWwY4Tpc44hSXO|YYm= MWmyNOKhyrWP MWq0POKhcA>? NHvLR|NFVVOR MkfXbY5kemWjc3XzJJRp\SCmaX\m[ZJmdnSrYYTpc44hd2ZiQnXXc{Bk\Wyucx?= NYLXWINTOjV3Nk[3OFA>
BeWo MlvPSpVv[3Srb36gRZN{[Xl? M2C4WVIxyqEEtV2= NUjoO4VOPDkEoHi= M1rwcmROW09? MY\pcoNz\WG|ZYOgeIhmKGGmaHXzbY9vKG:oIGTIVE0yKG2xbn;jfZRmew>? NVPON|M4OjV3Nk[3OFA>
LNCaP  MX\GeY5kfGmxbjDBd5NigQ>? M4LGN|ExyqEQvF2= Mn70NVIhcMLi MXHEUXNQ M32yN4lv\HWlZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBw\iCFUlXCNUBi[3Srdnn0fS=> NXLZcHVzOjV3NEiwPVk>
ThGCs  NUPhbGNHTnWwY4Tpc44hSXO|YYm= NEXuZpYyOOLCit88US=> NYT2T3BCPOLCini= MkWyZZVodWWwdIOgTGlHOUFibHX2[Yx{KHSqYYSge4Vz\SC|dHnteYxifGWmIHL5JGNwS2x{ MnrtNlU1OzNyMke=
ThGCs  M{HFOmZ2dmO2aX;uJGF{e2G7 MkjWNVDjiIsQvF2= Mk\4OQKBkmh? NU\DfHFncW6lcnXhd4V{KEOxQ3yyMYlv\HWlZXSgSWRPOsLiZ3Xu[UBmgHC{ZYPzbY9v NX;abYkxOjV2M{OwNlc>
ThGCs  M2q1UGZ2dmO2aX;uJGF{e2G7 NVnjN5dROTEkgJtOwG0> NV3BTZZ3OyCq NUXqOGU5cW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?= MWOyOVQ{OzB{Nx?=
RBMECs NXPJZo5VTnWwY4Tpc44hSXO|YYm= NHnBfWkxNjB3L{CuOU82KM7:TR?= MXiwMlI2KGh? MXfpcoNz\WG|ZYOgZ2FOWCClb37j[Y51emG2aX;u NGnwNpczPTRzNk[1NS=>
RBMECs MmXiSpVv[3Srb36gRZN{[Xl? NIK0ZZA2yqEQvF2= NFq0V5EyKGh? Mmn3Zoxw[2u|IITo[UBi[3SrdnH0bY9vKG:oIGLoc2EwWk:FSzDpcoR2[2WmIHL5JGVOSVBvSVm= NXXQc3JPOjV2MU[2OVE>
RBMECs MVXGeY5kfGmxbjDBd5NigQ>? Mlv5OeKh|ryP MkLLNUBp MWTwdoV3\W62czD0bIUhTU2DUD3JTU1qdmS3Y3XkJHRGTVJidnHseYUh\GWlcnXhd4U> NXvzfXZNOjV2MU[2OVE>
RBMECs MYnGeY5kfGmxbjDBd5NigQ>? M1;ke|XDqM7:TR?= MX[xJIg> MULwdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iSGLQJIZtfXhiYXPyc5N{KHSqZTDCWGIhcW6mdXPl[EBjgSBiRV3BVE1KUQ>? M1vtWlI2PDF4NkWx
RBMECs NH3BW3lHfW6ldHnvckBCe3OjeR?= MlfxOeKh|ryP NXPpVHU4OSCq NH;LWpVqdmirYnn0d{B1cGViZHXjdoVie2WmIH;mJIFud3WwdDDv[kBbVy1zIHnuJG1HeyCrbnT1Z4VlKGK7IFXNRXAuUUl? NYHLXVNJOjV2MU[2OVE>
RBMECs MUTGeY5kfGmxbjDBd5NigQ>? NVjUcJp4PcLizszN NETS[3oyKGh? NFvuV|hz\X[ncoPld{B1cGViY3jhcodmeyCrbjDaU{0yKGSrc4TybYJ2fGmxbjDz[YVvKHerdHigSW1CWC2LSTD0doVifG2nboS= M{LiU|I2PDF4NkWx
RBMECs Mnz2SpVv[3Srb36gRZN{[Xl? MWm1xsDPxE1? MXmxJIg> NX7zVIFX[myxY3vzJJRp\SCHTVHQMWlKNWmwZIXj[YQh[2ijbnflJIlvKE2OQzDwbI9{eGixconsZZRqd25? NH;0ZmMzPTRzNk[1NS=>
RBMECs MnLYSpVv[3Srb36gRZN{[Xl? MY[1xsDPxE1? NFfWdJYyKGh? MXLicI9kc3NidHjlJIFkfGmwIHP5eI9{c2WuZYTvckBz\WG{cnHu[4Vu\W62IIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdNMg MlrsNlU1OTZ4NUG=
Primary bovine chondrocytes MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jI[FXPxE1? M{HHcVQ5KGh? NILPVIhz\X[ncoPld{B1cGViaX7obYJqfG:{eTDl[oZm[3Rib3[gZ4Vt\WOxeHniJI9vKHC{b3zp[oVz[XSrb36gbY4h\3Kxd4ToJJBt[XSnIHPoc45lem:leYTldy=> NHrDXpYzPTRyNkCxOi=>
EM1  NWLoV3JSTnWwY4Tpc44hSXO|YYm= Mn;NNVXjiIsQvF2= MWS0PEBp NVTOW2FUemWmdXPld{B1cGViZYjwdoV{e2mxbjDv[uKhVEmIwrDvduKhWFSJU{NCpIlvyqCFQVzSMUBwesLiRWDBR|Iue2muZX7j[YQhTU1zIHPlcIx{yqB? MUSyOVM4QDZ4MR?=
BeWo  MVnGeY5kfGmxbjDBd5NigQ>? NHjJOHMzOMLiwsXN NHfmXWc1QMLiaNMg M3jPNmROW00EoB?= NIjwVIpqdmO{ZXHz[ZMhfGinIHLleIEucEOJIILlcIVie2V? MVOyOVM3OjJ4MB?=
BeWo  NXPVSYJ7TnWwY4Tpc44hSXO|YYm= NUTlUY5kOjEEoNM1US=> MVy0POKhcMLi MljTSG1UV8Li NF;zS|Vld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 NE[3ZY0zPTN4MkK2NC=>
BeWo  NEj6cYpHfW6ldHnvckBCe3OjeR?= NYPpSVlrOjEEoNM1US=> M2ewTFQ5yqCqwrC= MkfqSG1UV8Li NEjpPGhld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBIS01vMR?= NVv2enZjOjV|NkKyOlA>
granulosa cells MYfGeY5kfGmxbjDBd5NigQ>? NVXpc4NrOTBizszN MYmxNk8zPCCq MnvXbY5kemWjc3XzJJRp\SCuZY\lcJMhd2cEoGLHV|LDqG2UTlG= MkLJNlU{OzlzMEW=
granulosa cells MXzGeY5kfGmxbjDBd5NigQ>? MX2xNEDPxE1? MUKxNk8zPCCq MnfZbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicnXwc5J1\XJiYXP0bZZqfHliZn;yJJRp\SCub37n[ZN1KG[{YXft[Y51KCkkiKK4OVQwMzF6UlfTNk5NXUNr NWLC[m5OOjV|M{mxNFU>
granulosa cells M2PWZmZ2dmO2aX;uJGF{e2G7 NXXRZ4JwOTBizszN MmXiNlQhcA>? MomybY5kemWjc3XzJJRp\SCrboTlcpNqfHlib3[gSG5CN3C{b4TlbY4h[2:vcHzlfC=> MlLINlU{OzlzMEW=
granulosa cells NVK2bop3TnWwY4Tpc44hSXO|YYm= M{OxZlExKM7:TR?= M{DEWVI1KGh? MmnTbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUlfTNkBxem:vb4TldkBi[3Srdnn0fS=> MYqyOVM{QTFyNR?=
SK-N-AS  NVPxflN1S2WubDDWbYFjcWyrdImgRZN{[Xl? NVnRVWdPOTBizszNxsA> M2HPNVI1NzR6IHi= MkjD[Y5p[W6lZYOgeIlu\S2mZYDlcoRmdnSueTDj[YxtfWyjcjD2bYFjcWyrdIpCpC=> M1LrXFI2OjZ4ME[z
SK-N-AS  M4PLbGZ2dmO2aX;uJGF{e2G7 NU\MbHUxOTBizszNxsA> NGHCT3czPCCq NWX6VJREcW6lcnXhd4V{KHSqZTDjRW1RKGyndnXsd:Kh M3vCe|I2OjZ4ME[z
SK-N-AS  NFn3b45HfW6ldHnvckBCe3OjeR?= MVyxNEDPxE4EoB?= NW\LVmduOjRiaB?= M4T3ZYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBkgWOuaX6gSFE> NVfrcoZYOjV{Nk[wOlM>
SK-N-AS  NIC1empHfW6ldHnvckBCe3OjeR?= MkCxNVAh|ryPwrC= NYPrO25nOzBibXnu MYTpcoR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjFOtk1k[XSnbnnuJEh{\XJ4N{WpMEBxNUeVS{ROtkApe2W{OTmgZY5lKGOxbnPvcYl1[W62IHjp[4hmeiCuZY\lcJMhd2ZiYXP0bZZmNCC3boDoc5NxcG:{eXzheIVlNCEQsj3jZZRmdmmw NInifogzPTJ4NkC2Ny=>
SK-N-AS  Mlr4SpVv[3Srb36gRZN{[Xl? NW\OXo1xOTBizszNxsA> Mln3NVAwOzBxNkCgcYlv MoTqbY5kemWjc3XzJIxmfmWuczDv[kBxNc7{LXPheIVvcW5iKIPldlY4PSliYX7kJIlv\HWlZYOgZYNkfW23bHH0bY9vKG:oIICt{tIu[2G2ZX7pckApe2W{Nke1LUBqdiBqcHXybUlvfWOuZXHyJJJm\2mxboO= M2n5U|I2OjZ4ME[z
SK-N-SH NVH5fHNmS2WubDDWbYFjcWyrdImgRZN{[Xl? M{HEUVExKM7:TdMg NV:0cnVkPDhiaB?= NFXMV5JmdmijbnPld{BUUy2QLWPIJI5mfXKxYnzhd5RwdWFiY3XscEB3cWGkaXzpeJk> M{HmfFI2OjZ4ME[z
HEK‐CFTR M4jsfWZ2dmO2aX;uJGF{e2G7 M4TsfVLjiJN3MNMg{txO NH\Ve3UxNTF{IH3pci=> NGTlblBFVVORwrC= MVnpcoR2[2W|IHGg[I9{\eLCkHTldIVv\GWwdDDpc4Rq\GViZX\mcJV5yqB? NEKwfoczPTJ4M{KwOy=>
L6 MX;GeY5kfGmxbjDBd5NigQ>? M1PNUVQxKML3TR?= NV;L[404OjRiaB?= NGexXotqdmirYnn0d{BFVUhzLXnu[JVk\WRiQXv0JIFkfGm4YYTpc44> MWqyOVI1PzV3MB?=
MIN6  NV3kWVdmTnWwY4Tpc44hSXO|YYm= MWexNEDPxE4EoB?= MVSzJIg> Mn\zbY5kemWjc3XzJGQ{KG2UTlGg[ZhxemW|c3nvci=> MYCyOVI1OTF{NB?=
ventricular cardiomyocytes  MWnGeY5kfGmxbjDBd5NigQ>? M4TndVAvODFvMUCg{txO M{jheIlv[3KnYYPld{Ah[0GPUDDhZ4N2dXWuYYTpc44> Mo\PNlUzODNzMUO=
ventricular cardiomyocytes  NEXCZVFHfW6ldHnvckBCe3OjeR?= NUPQZ3JLOC5yMT2xNEDPxE1? MoG0[ZZwc2W|IHHuJIlvd3S{b4DpZ{Bz\XOyb37z[UAyOjEEsUG1KUBi[m:4ZTDiZZNidCC5aYToJIFvKEWFNUFCpI9nKDJwMjFCuW0> M{HifVI2OjB|MUGz
BeWo  NVj0PGxqTnWwY4Tpc44hSXO|YYm= NWfZXFFtOjBiwsXN M3n2[lQ5KGh? M13vcWROW00EoB?= MnnNbY5lfWOnczDj[YxtKG[3c3nvci=> MlvtNlUyQDR2N{e=
THP-1  NVzDOJViTnWwY4Tpc44hSXO|YYm= MV6xM|ExKM7:TR?= M3fkRVLDqGh? MUjEUXNQyqB? Mnn5d5VxeHKnc4Pld{BOS1BvMTDwdo9lfWO2aX;uxsA> MmLlNlUyPTR6OEK=
Huh-7 MXzGeY5kfGmxbjDBd5NigQ>? MnS0NE0zOCEQvF2= M1\aOFIhcMLi MWPy[ZN2dHS|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4h[y2PeXOg[ZhxemW|c3nvckBifCC2aHWgdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHN? NX3OeoM4OjVzMEm4N|Q>
C6 M4HhOmZ2dmO2aX;uJGF{e2G7 M4LZeVExKM7:TdMg NF[2dGMzOCCvaX6= M{\jV4lv[3KnYYPld{BkSU2SIHHjZ5VufWyjdHnvci=> MoHBNlUxPjl2MUe=
SW480 NFy3VllHfW6ldHnvckBCe3OjeR?= NFnlNpQ1OMLizszN MnG3OFjDqGh? M17HcGROW09? NF7Ve2Ji[3SrdnH0[ZMhWFB{QR?= NUDEN3A6OjR7OUe0OVE>
HT-29  NWnUZpRYTnWwY4Tpc44hSXO|YYm= MkHLOFDDqM7:TR?= MoDKOFjDqGh? MWXEUXNQ MYHhZ5RqfmG2ZYOgVHAzSQ>? MUiyOFk6PzR3MR?=
SW480 NGn2PY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX6R3hXPDEEoN88US=> MX2wMVczKGh? MlXESG1UVw>? NYPvd2NycW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? NILpV3ozPDl7N{S1NS=>
HT-29  MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X0WFQxyqEQvF2= NFnZWoMxNTd{IHi= NIPFOnFFVVOR MoLWbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> MkHhNlQ6QTd2NUG=
SW480 MYfGeY5kfGmxbjDBd5NigQ>? MX:0NOKh|ryP MofzO{Bl NXmySmNrTE2VTx?= NFzwbmJz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg NYe5[moyOjR7OUe0OVE>
HT-29  MYTGeY5kfGmxbjDBd5NigQ>? MnnPOFDDqM7:TR?= NVTqcVFbPyCm Mm\nSG1UVw>? MoPpdoVlfWOnczDjc4xwdm:|cHjldoUh\m:{bXH0bY9vKGOjcHHibYxqfHoEoB?= M{PuOFI1QTl5NEWx
SW480 MnnHRZBweHSxc3nzJGF{e2G7 M1r5VlQxyqEQvF2= MljCOFjDqGh? NHv6UVBFVVOR NYXn[FlCcW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 M2jsWlI1QTl5NEWx
HT-29  MmH5RZBweHSxc3nzJGF{e2G7 MUG0NOKh|ryP MYS0POKhcA>? M2rLT2ROW09? MYPpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= NEfkWIgzPDl7N{S1NS=>
SW480 NV;ofWpvSXCxcITvd4l{KEG|c3H5 NUT3Tow5PDEEoN88US=> M4KxVFQ5yqCq NXTpfnY5TE2VTx?= M{nSNolv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= MlnWNlQ6QTd2NUG=
HT-29  M3XxN2Fxd3C2b4Ppd{BCe3OjeR?= M2PT[|QxyqEQvF2= NHvwOWE1QMLiaB?= MYnEUXNQ MorFbY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= NI\BO2MzPDl7N{S1NS=>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Water Insoluble
Ethanol '37 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.5
化学式

C22H34O7
CAS号 66575-29-9
储存条件 粉状
溶于溶剂
别名 Coleonol

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

cAMP Signaling Pathway Map
Tags: 购买Forskolin | Forskolin供应商 | 采购Forskolin | Forskolin价格 | Forskolin生产 | 订购Forskolin | Forskolin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID